Lenalidomide in Diffuse Large B-Cell Lymphoma

Table 1

Response to Lenalidomide in relapsed/refractory diffuse large B-cell lymphomas.

Lenalidomide	Monotherapy		Association
Name of the protocol	NHL002 [52]	NHL003 [53]	Lenalidomide and rituximab [54]
Year of publication	2008	2011	2011
Type of study	Multicentric	International	Multicentric
Phase	Phase II	Phase II	Phase II
Treatment	Lenalidomide	Lenalidomide	Lenalidomide and rituximab
Dose of lenalidomide:	25 mg/d, D1–21	25 mg/d, D1–21	20 mg/d, D1–21
	every 28 days	every 28 days	every 28 days
Duration or treatment or; No. of cycles	52 weeks	—	4 cycles; + maintenance (𝑛=10 pts)
No. of patients	49	267	23
No. of DLBCL	26	108	23
Response*			Induction	Complete therapy
ORR 𝑛, (%)	5 (19)	30 (28)	8 (35)	8 (35)
CR 𝑛, (%)	1 (3)	8 (7)	7 (31)	8 (35)
CRU 𝑛, (%)	2 (8)	—	—
PR 𝑛, (%)	2 (8)	22 (20)	1 (4)	0 (0)
Stable disease 𝑛, (%)	7 (27)	23 (21)	2 (8)	2 (8)
Progression 𝑛, (%)	14 (54)	40 (37)	13 (57)
Followup		9.2	16
Median time to response (month)	PR: 1.9 (1.2–3.7); CR: 4.3 (1.9–10.5)	1.9 (1.4–11.5)	—
Median response duration (month)	6.2 (0–12.8)	1.6	—
PFS, Median (month)	4	2.7	1-year DFS 34.8%

ORR: overall response rate, CR: complete response, CRU: complete response unconfirmed, PR: partial response, PFS: progression free survival.
NHL002: the results of response are specifically reported for DLBCL.
NHL003: the results of response are specifically reported for DLBCL.